Chemistry:LY03017

From HandWiki

LY03017, also known as LPM-526000133, is a serotonin 5-HT2 receptor antagonist which is under development for the treatment of schizophrenia[1][2][3] and Alzheimer's psychosis.[4] It acts specifically as a dual serotonin 5-HT2A receptor inverse agonist and serotonin 5-HT2C receptor antagonist.[1][2][3] The drug is under development by Luye Pharma Group in China.[1][2] As of December 2025, it is in phase 1 clinical trials.[1][2][3] The chemical structure of LY03017 does not yet appear to have been disclosed.[1]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 "LY 03017". 31 December 2025. https://adisinsight.springer.com/drugs/800078298. 
  2. 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on LPM526000133 with Synapse". 24 January 2026. https://synapse.patsnap.com/drug/6f1b82909ba34008986e56f0c1adc300. 
  3. 3.0 3.1 3.2 "LY-03017 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/33824. 
  4. "Hypothesis-Driven Insights and Clinical Trial Updates in Alzheimer's Disease Pathogenesis". CNS & Neurological Disorders Drug Targets. October 2025. doi:10.2174/0118715273387383250924031644. PMID 41126430.